Corporate Governance
Corporate Governance Is Killing Your Pharmaceutical ESG ROI
Corporate Governance Is Killing Your Pharmaceutical ESG ROI The European Investment Bank’s €500 million green bond highlights the funding potential for pharma firms that align ESG metrics with long-term antibiotic strategies; otherwise, corporate governance that ignores ESG can erode ESG ROI. Financial Disclaimer: This article is for educational purposes